Pfizer recalls sickle cell anaemia drug due to risk of complications and death
US drugmaker Pfizer said on Wednesday it was recalling Oxbryta, a treatment for sickle-cell anaemia, from all markets where it is approved, citing risks of painful complications and fatalities. Pfizer acquired Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022.
BELIEBTE BEITRÄGE
Trump opts for personal ties to choose his government team
November 15, 2024
UK sets new climate target for 2035
November 13, 2024
Children go back to school after Valencia floods
November 13, 2024
Researchers document huge decline in African elephants
November 13, 2024
LIVEÜBERTRAGUNG